In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different β-lactam resistance phenotypes
Résumé
The study evaluated the activity of ceftolozane-tazobactam (C/T) against 94 unique clinical isolates of complex (ECC). No difference was observed according to the ECC cluster. The activity greatly varied depending on the β-lactamase-producing profile: 100%, 67%, and 19% of wild-type, extended-spectrum β-lactamase (ESBL)-producing, and AmpC-overproducing strains, respectively, were susceptible to C/T. The use of C/T could be of interest for the treatment of some infections caused by ESBL-producing AmpC-nonoverexpressing ECC isolates.
Fichier principal
Robin - In vitro activity of ceftolozane-tazobactam.pdf (698.28 Ko)
Télécharger le fichier
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|
Loading...